Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.128 enrolled

Overview

The main purpose of this study is to evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

128

Conditions

Cerebrovascular Accident Hypercholesterolemia

Interventions

AtorvastatinDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * clinically defined lacunar syndrome 3 months before inclusion * small deep infarct on diffusion MRI (Diffusion Weighted Imaging) * no atherothrombotic, cardio-embolic, or other rarer cause. Exclusion Criteria: * patients with past coronary event * contra-indication for assessment of vasomotor reactivity * patients being on statin therapy at the time of brain infarction * contra-indication for statin therapy * patient still under statin therapy

Locations (1)

Pfizer Investigational Site

Paris, France

Outcomes

Primary Outcomes

Evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients. CVR, humeral and carotid vasoreactivity will be measured in all patients at M0 and M3.

Secondary Outcomes

Evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on endothelium dependant and independent vasomotoricity of humeral and / or common carotid artery (according to validation study) in lacunar patients.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.